ASMULAIR is indicated as an additive treatment in patients with mild to moderate persistent asthma insufficiently controlled by inhaled corticosteroid therapy and in whom short-acting, immediate-acting beta2 mimetics administered "on demand" do not provide sufficient clinical control of the asthma. 'asthma. For these same patients in whom ASMULAIR is indicated for asthma, ASMULAIR may at the same time provide symptomatic relief of seasonal allergic rhinitis. ASMULAIR is also indicated for preventive treatment of exercise-induced asthma.